The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksN4 Pharma Plc Regulatory News (N4P)

Share Price Information for N4 Pharma Plc (N4P)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.80
Bid: 0.75
Ask: 0.85
Change: 0.00 (0.00%)
Spread: 0.10 (13.333%)
Open: 0.80
High: 0.80
Low: 0.80
Prev. Close: 0.80
N4P Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Directorate Change

21 Feb 2011 07:00

RNS Number : 5387B
Ultima Networks PLC
21 February 2011
 



21 February 2011

 

Ultima Networks plc

('Ultima' or the 'Company')

 

Appointment of Executive Director

 

The Board of Ultima is pleased to announce the appointment of Matteo Turi to its Board as an Executive Director of the Company with effect from 1 April 2011. Matteo will be responsible for the development of the Company's Green Power division and specifically for Ultima's solar power activities in Italy.

 

Matteo Turi (aged 39) is currently Finance Director at London-based RenGen Energy Group ("RenGen"), a renewable energy fund which sources, develops and finances renewable energy projects. RenGen's interests include equity and debt investments in renewable energy projects in Italy. Matteo joined RenGen in April 2008 where he has been, inter alia, responsible for all financial strategies and planning for RenGen's renewable energy investments. Matteo will initially continue to work with RenGen on a part-time basis.

 

Prior to joining RenGen, Matteo was European Financial Controller at K2 Partnering Solutions Ltd, a global provider of enterprise software consultants, from May 2007 to April 2008 where his role included business transformation and extensive change management. Previously Matteo was Divisional Financial Controller of Vanco plc, a Pan-European telecoms business, from May 1999 to March 2005 where he helped support the growth of Vanco during this period including the listing in 2001 of the company on the Official List of the London Stock Exchange. After leaving Vanco Matteo worked at International Poster Management, part of the Interpublic Group, as Divisional Financial Controller on a short term project and was Senior Overseas Financial Manager at Moneygram International Ltd where his role covered the integration of a major acquisition. Matteo has been a member of ACCA (the Association of Chartered Certified Accountants) since 2003.

 

Commenting on the board appointment, Prof. Humayun Mughal, the Company's Chairman and CEO, commented: "On behalf of the Board I would like to welcome Matteo onto the board and into his new role further strengthening our renewable energy capabilities. Matteo joins us with experience in the renewable energy sector at a time when we are looking to build upon our solar power credentials, particularly in Italy. We are confident that his experience will prove to be valuable to the growth of Ultima."

 

Matteo Turi is, or has been, a director of the following companies in the last 5 years:

 

Current Directorships/Partnerships:

 

Directorships/Partnerships within the last 5 years:

None

None

 

Matteo currently has no interest in the share capital of Ultima.

 

There are no further disclosures to be made in relation to Mr Matteo Turi under Schedule 2 (g) and rule 17 of the AIM Rules for Companies.

 

 

Ultima Networks plc

Prof. Humayun Mughal, Chairman and CEO

Tel: 01279 821 200

Allenby Capital Limited

(Nominated Adviser and Broker)

Tel: +44 (0)203 328 5656

Nick Naylor

Nick Athanas

Alex Price

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAFMGZZMGVGMZZ
Date   Source Headline
29th Apr 202410:59 amRNSPosting of Annual Report & Notice of AGM
26th Apr 20247:00 amRNSN4 Pharma Webinar on SRI Collaboration
25th Apr 20247:38 amRNSCollaboration Agreement with SRI International Inc
23rd Apr 20247:00 amRNSFinal Results
18th Apr 20247:00 amRNSOral Delivery Update
4th Mar 20243:13 pmRNSHolding(s) in Company
29th Feb 20247:00 amRNSHolding(s) in Company
15th Feb 20247:00 amRNSin-vitro siRNA update
19th Jan 20247:00 amRNSPatent Grant
18th Jan 202410:15 amRNSHolding(s) in Company
16th Jan 20247:00 amRNSNanogenics Update
8th Jan 20244:24 pmRNSHolding(s) in Company
8th Jan 20247:00 amRNSAAV Viral Vector Update
18th Dec 20237:00 amRNSOral Delivery Update
7th Dec 202311:28 amRNSHolding(s) in Company
7th Dec 20237:00 amRNSNuvec® R&D and Strategy Update
30th Nov 20239:00 amRNSN4 Pharma Launches New Interactive Investor Hub
31st Oct 20237:00 amRNSTotal Voting Rights
9th Oct 20237:00 amRNSInvestor Presentation via Investor Meet Company
3rd Oct 20238:15 amRNSHolding(s) in Company
2nd Oct 20237:00 amRNSInvestor Presentation
28th Sep 20237:00 amRNSAcquisition of Controlling Interest in Nanogenics
12th Sep 20237:00 amRNSInterim Results
25th Jul 20237:00 amRNSPatent Grant and Board Change
27th Jun 20237:00 amRNSGrant Award for Professor Chengzhong Yu
25th Apr 20237:00 amRNSsiRNA update
18th Apr 20237:00 amRNSsiRNA update
3rd Apr 20232:11 pmRNSResult of AGM
9th Mar 20237:00 amRNSPosting of Annual Report & Notice of AGM
9th Mar 20237:00 amRNSFinal Results
14th Feb 20234:40 pmRNSSecond Price Monitoring Extn
14th Feb 20234:35 pmRNSPrice Monitoring Extension
17th Jan 20232:05 pmRNSSecond Price Monitoring Extn
17th Jan 20232:00 pmRNSPrice Monitoring Extension
17th Jan 202311:05 amRNSSecond Price Monitoring Extn
17th Jan 202311:00 amRNSPrice Monitoring Extension
17th Jan 20239:05 amRNSSecond Price Monitoring Extn
17th Jan 20239:00 amRNSPrice Monitoring Extension
17th Jan 20237:00 amRNSOral application update
30th Nov 20225:28 pmRNSHolding(s) in Company
30th Nov 20227:00 amRNSTotal Voting Rights
25th Nov 20222:49 pmRNSHolding(s) in Company
22nd Nov 202210:50 amRNSResult of Broker Offer and Total Voting Rights
18th Nov 20227:01 amRNSBroker Offer to raise a maximum of £1 million
18th Nov 20227:00 amRNSPlacing to raise £1million and Broker Offer
1st Nov 20227:00 amRNSPatent filing update
4th Oct 20227:00 amRNSDouble siRNA Testing Update
29th Sep 20227:00 amRNSInterim Results
14th Sep 20227:00 amRNSOperational Update
15th Jul 20227:00 amRNSWork Programme Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.